Synergistic bactericidal activity of a naturally isolated phage and ampicillin against urinary tract infecting Escherichia coli O157

Document Type : Original Article


1 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran

2 Cellular and Molecular Sciences Research Center, Urmia University of Medical Sciences, Urmia, Iran


Objective(s): Bacteriophages are infectious replicating entities that are under consideration as antimicrobial bioagents to control bacterial infections. As an alternative or supplement to antibiotics, bacteriophages can be used to circumvent the resistance to existing antibiotics. The aim of this study was to assess the synergistic effect of a naturally isolated phage and ampicillin against Escherichia coli O157.
Materials and Methods: In the present study, a natural phage against E. coli O157 was isolated, the morphology and molecular characteristics of the phage were identified, and the combination of bacteriophage and antibiotic to combat clinically isolated drug-resistant E. coli O157 was evaluated.
Results: The results showed the synergistic action between a naturally isolated phage and ampicillin in solid (disk diffusion test) and liquid culture media. Addition of the isolated phage,, to the microbial lawn of bacteria in modified antibiotic disk diffusion test, altered susceptibility pattern of E. coli O157 from resistant to sensitive based on the inhibition zones. Combinations of bacteriophage and ampicillin significantly enhanced the killing of bacterial strains when compared to treatment with ampicillin or phage alone in liquid culture. Moreover, it lasted few hours for ampicillin to reverse the growth of E. coli O157, while the bacteriophage and combination treatment stopped the proliferation of bacteria from the beginning, and this can compensate the delayed onset of antibiotic action.
Conclusion: The synergistic action of bacteriophages and antibiotics is an alternative that cannot only be effective against bacterial infections but also contribute to the reduction of antibiotic resistance.


1. Dalmasso M, Strain R, Neve H, Franz CM, Cousin FJ, Ross RP, et al. Three new Escherichia coli phages from the human gut show promising potential for phage therapy. PLoS One 2016; 11:e0156773.
2. Ghasemian A, Bavand M, Moradpour Z. A broad-host range coliphage against a clinically isolated E. coli O157: isolation and characterization. J Appl Pharma Sci 2017; 7:123-128.
3. Moradpour Z, Sepehrizadeh Z, Rahbarizadeh F, Ghasemian A, Yazdi MT, Shahverdi AR. Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli. FEMS Microbiol Lett 2009; 296:67-71.
4. Moradpour Z, Ghasemian A. Isolation and identification of a natural bacteriophage as a biocontrol agent against Proteus vulgaris, Res J Biotechnol 2019; 14: 63-66.
5. Oloketuyi SF, Khan F. Inhibition strategies of Listeria monocytogenes biofilms-current knowledge and future outlooks. J Basic Microbiol 2017; 57:728-743.
6. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, et al. Quality and safety requirements for sustainable phage therapy products. Pharm Res 2015; 32:2173-2179.
7. Oliveira H, Sillankorva S, Merabishvili M, Kluskens LD, Azeredo J. Unexploited opportunities for phage therapy. Front Pharmacol 2015; 6:180-183.
8. Örmälä A-M, Jalasvuori M. Phage therapy: should bacterial resistance to phages be a concern, even in the long run? Bacteriophage 2013; 3:e24219.
9. Comeau AM, Tétart F, Trojet SN, Prere M-F, Krisch H. Phage-antibiotic synergy (PAS): β-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2007; 2:e799.
10. Torres-Barceló C, Hochberg ME. Evolutionary rationale for phages as complements of antibiotics. Trend Microbiol 2016; 24:249-256.
11. Henry M, Biswas B, Vincent L, Mokashi V, Schuch R, Bishop-Lilly KA, et al. Development of a high throughput assay for indirectly measuring phage growth using the OmniLog(TM) system. Bacteriophage, 2012; 2: 159-167.
12. Ryan EM, Alkawareek MY, Donnelly RF, Gilmore BF. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol 2012; 65:395-398.
13. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998; 11:450-479.
14. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet 1998; 352:1207-1212.
15. Kitov PI, Sadowska JM, Mulvey G, Armstrong GD, Ling H, Pannu NS, et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000; 403:669-672.
16. Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 2000; 6:265-270.
17. Judge NA, Mason HS, O’Brien AD. Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of Escherichia coli O157:H7 shedding in feces. Infect Immun 2004; 72:168-175.
18. Moradpour Z, Ghasemian A. Modified phages: novel antimicrobial agents to combat infectious diseases. Biotechnol Adv 2011; 29:732-738.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
20. San Martín C, Huiskonen JT, Bamford JK, Butcher SJ, Fuller SD, Bamford DH, et al. Minor proteins, mobile arms and membrane–capsid interactions in the bacteriophage PRD1 capsid. Nat Struct Mol Biol 2002; 9:756-763.
21. Patel J, Cockerill F, Alder J, Bradford P, Eliopoulos G, Hardy D, et al. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI 2014; 34:1-226.
22. Jo A, Kim J, Ding T, Ahn J. Role of phage-antibiotic combination in reducing antibiotic resistance in Staphylococcus aureus. Food Sci Biotechnol 2016; 25:1211-1215.
23. Uddin MJ, Easwaran M, Ahn J. Characterization of bacteriophages specificity for antibiotic-resistant Salmonella typhimurium. Ann Microbiol 2018; 68:637-643.
24. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre AS, Lavigne R. Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci 2012; 13:699-722.
25. Ackermann HW. Phage classification and characterization. Methods Mol Biol 2009; 501:127-140.
26. Jo A, Ding T, Ahn J. Synergistic antimicrobial activity of bacteriophages and antibiotics against Staphylococcus aureus. Food Sci Biotechnol 2016; 25:935-940.
27. Torres-Barceló C, Arias-Sánchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One 2014; 9:e106628.
28. Kamal F, Dennis JJ. Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): Antibiotics stimulate lytic phage activity. Appl Environ Microbiol 2014: AEM. 02850-02814.
29. Melo LD, Veiga P, Cerca N, Kropinski AM, Almeida C, Azeredo J, et al. Development of a phage cocktail to control Proteus mirabilis catheter-associated urinary tract infections. Front Microbiol 2016; 7:1024-1035.
30. Summers WC. Bacteriophage therapy. Annu Rev Microbiol 2001; 55:437-451.
31. Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 2016; 6:26717-26724.